Cell receptor may lead to new 'biomarker' for pancreatic cancer

Jul 01, 2007

A research team led by University of Cincinnati (UC) scientists has identified a potential biological target for pancreatic cancer, a finding they say could help scientists better understand -- and eventually treat -- the disease that kills more than 33,000 people each year.

In laboratory studies led by Andrew Lowy, MD, and Susan Waltz, PhD, the Cincinnati researchers found that a specific cell receptor -- known as the RON receptor tyrosine kinase -- was “overexpressed,” or increased, in pancreatic cancer cells. This, says Waltz, suggests the receptor may also contribute to the disease’s development.

The RON receptor has been found to be active in several cancers -- including breast cancer -- but its role in pancreatic cancer was unknown. This is one of the first studies, published in the July 1, 2007, issue of the journal Cancer Research, to report a link between the RON receptor and pancreatic cancer.

Receptor tyrosine kinases are proteins on the cell surface used to activate specific body functions -- for example cell growth and migration.

“A normal pancreas has very low levels of RON, but our study showed that as tumors progress, so does the level of RON expression in the pancreas cells -- and those overexpressed levels were maintained in ‘metastases,’ the areas that the tumors spread to,” explains Waltz, associate professor and director of the oncology research program in UC’s surgery department.

The team found that the RON receptor was active in 93 percent of what is known as pancreatic intraepithelial neoplasia, an early form of pancreatic duct cancer. In addition, the receptor was present in 79 percent of primary pancreatic cancers and 83 percent of metastatic cancers.

UC researchers believe the RON receptor’s signaling pathways could be a key factor contributing to pancreatic cancer progression. Waltz says if the receptor could be blocked, it would give drug developers a new target for RON-directed therapies that are more effective in treating this deadly disease.

“When cells became invasive,” Waltz said, “we saw higher levels of RON expression that correlated with the aggressive nature of this disease and cancer metastasis. Clearly, this signaling pathway is associated with pancreatic cancer and merits further investigation.”

A relatively rare but difficult disease to treat, pancreatic cancer will affect about 37,000 Americans in 2007. According to the National Cancer Institute, overall survival for the disease is only about 4 percent -- often because the disease spreads before it can be clinically detected.

In the December 2006 issue of Cancer Research, Waltz reported that the RON receptor can also be involved in breast cancer. Based on those earlier findings, she and Lowy wanted to know if the receptor was also expressed in pancreatic cancer -- an aggressive, highly metastatic cancer -- and whether it played a role in disease development.

For the UC study, researchers used the protein HGFL (hepatocyte growth factor-like) to activate the RON receptor. Although stimulating the RON receptor had no effect on pancreatic cell growth, blocking it with targeted antibodies killed more cancer cells than did the standard treatment drug gemcitabine (gem-SITE-uh-bean) alone.

“Our findings suggest that combining antibodies that block the RON receptor and the standard chemotherapy drugs might stop progression of pancreatic cancer more effectively,” says Waltz. “RON could be a promising molecular target for future cancer drug development.”

Waltz stresses, however, that additional preclinical research is needed before RON receptor blockers become available for human testing.

Source: University of Cincinnati

Explore further: Cancer researchers identify irreversible inhibitor for KRAS gene mutation

add to favorites email to friend print save as pdf

Related Stories

Google made failed bid for Spotify

3 hours ago

Internet titan Google tried last year to buy streaming music service Spotify but backed off for reasons including a whopping price tag, the Wall Street Journal reported on Tuesday.

Thieves got into 1K StubHub accounts

3 hours ago

(AP)—Cyber thieves got into more than 1,000 StubHub customers' accounts and fraudulently bought tickets for events through the online ticket reseller, a law enforcement official and the company said Tuesday.

Microsoft CEO sees 'bold' plan as 4Q tops Street

3 hours ago

(AP)—Microsoft Corp. CEO Satya Nadella painted an upbeat vision of the future Tuesday, saying that the next version of Windows will be unified across screens of all sizes and that two money-losing units—Nokia ...

Recommended for you

Generation of tanners see spike in deadly melanoma

1 hour ago

(AP)—Stop sunbathing and using indoor tanning beds, the acting U.S. surgeon general warned in a report released Tuesday that cites an alarming 200 percent jump in deadly melanoma cases since 1973.

Penn team makes cancer glow to improve surgical outcomes

1 hour ago

The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence.

Cancer: Tumors absorb sugar for mobility

13 hours ago

Cancer cells are gluttons. We have long known that they monopolize large amounts of sugar. More recently, it became clear that some tumor cells are also characterized by a series of features such as mobility or unlikeliness ...

User comments : 0